This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Faecal microbiota transplantation (FMT) in ulcerative colitis (UC)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Fecal Microbiota Transplantation (FMT) is the process of introducing faecal material from a highly screened, healthy donor into an unwell recipient’s gastrointestinal tract to restore the healthy homeostatic properties of the gut ecosystem and alleviate symptoms

  • most common methods of FMT administration involve liquefying donor stool in saline, filtering to remove solid components, and then infusing the contents either colonoscopically, via enema or less commonly through the upper gastrointestinal tract via nasojejunal tube

  • FMT in ulcerative colitis
    • a small RCT (n=35) found antibiotics followed by orally administered faecal microbiota transplantation was associated with superior induction of remission in patients with active ulcerative colitis vs antibiotics followed by placebo (53% vs 15%;p=0.027; OR 5.0, 95% CI 1.8-14.1) (2)

Reference:

  • Borody TJ, Clancy A. Fecal microbiota transplantation for ulcerative colitis-where to from here?. Transl Gastroenterol Hepatol. 2019;4:48. Published 2019 Jun 26. doi:10.21037/tgh.2019.06.04
  • Haifer C et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterology & Hepatology, ISSN:2468-1253.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.